Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Files in this item

Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics